Inovio Pharmaceuticals vs NeOnc Technologies
INO and NTHI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INO and NTHI compare
Inovio Pharmaceuticals is the larger company, worth 1.5 times as much as NeOnc Technologies ($169M against $112M).
Inovio Pharmaceuticals scores higher on the StockData Score (4 against 0 for NeOnc Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INO | NTHI |
|---|---|---|
| Size and price | ||
| Market cap | $169M | $112M |
| Share price | $1.63 | $4.33 |
| Change, 1 year | −20.5% | −52.3% |
| Change, 5 years | −98.1% | – |
| Beta (5Y) | −0.26 | 2.81 |
| Employees | 27 | 5 |
| StockData Score | ||
| Total score | 4 (better) | 0 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 4 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 38.6× | – |
| FCF yield | −47.9% | – |
| Growth | ||
| Revenue growth (TTM) | −100% | – |
| Revenue growth, 5Y average | −61.2% | – |
| Profitability | ||
| Return on equity | −410% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −15.7× |
| Current ratio | 1.00 (better) | 0.38 |
| Altman Z-score | −55.23 | −34.30 (better) |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Buyback yield | −22.6% | – |
| Shareholder yield | −22.6% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 31.7% | 12.2% |
| Held by insiders | 0.38% | 60.1% |
| Insider net buying, 12 months | – | $2.0M |
| Short interest, % of float | 21.5% | 8.9% |
Go deeper
- INO stock overview
- INO income statement
- INO valuation and score
- NTHI stock overview
- NTHI income statement
- NTHI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.